An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Double-blind Study
Latest Information Update: 20 Jan 2022
At a glance
- Drugs Micafungin (Primary)
- Indications Invasive candidiasis; Mycoses
- Focus Therapeutic Use
- Acronyms INTENSE
- Sponsors Astellas Pharma; Astellas Pharma Europe Ltd
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 02 Nov 2017 New trial record